BLU-U BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATORE BLU-U 10K MODEL 4170-ID

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05 report with the FDA on 2013-11-12 for BLU-U BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATORE BLU-U 10K MODEL 4170-ID manufactured by Dusa Pharmaceuticals, Inc..

Event Text Entries

[20104475] (b)(6) old male patient with facial actinic keratoses (ak's) who was treated for the first time with levulan kerastick 20% topical solution and blu-u photodynamic therapy (pdt) on the nose and cheeks (face) on (b)(6) 2013. Pre-treatment skin prep consisted of an alcohol wipe and drying of the face. Levulan was applied to his nose and cheeks, with an incubation time of one hour, followed by blu-u light exposure with 16 minutes 40 seconds. The patient tolerated the treatment with no complaints, left the dermatologist office in stable condition and drove home, reportedly 1. 5 hrs. On (b)(6) 2013, two days post treatment, he experienced a seizure, was taken to the hospital for evaluation, and admitted. An mri was scheduled for (b)(6) 2013, patient remains hospitalized, and the cause of the seizure is still unknown. There is no medical history of seizure disorder, or concomitant medications to indicate such. On (b)(6) 2013 the patient's wife reported: two days post treatment (b)(6) 2013, at about 6:50 am, she awoke to find her husband was having a seizure. Emergency medical treatment (emt's) transported him to the hospital. When she arrived at the hospital, shortly after her husband arrived, she reports her husband was intubated and sedated. He was admitted to the cardiac intensive care unit (cicu), where he was monitored with continuous eeg, and sedation (versed). She reports that he continued to have seizures for the next two days. An mri was done and the results were "unremarkable. " the versed was decreased in small doses while they kept the seizures under control. After the seizure activity stopped, and being completely weaned from the versed for one day, he was taken off the vent and has maintained a good oxygen level of 95%. He is being considered for transfer to a step down neuro unit. The wife reported he is awake, alert, and oriented to person, place and time, and getting out of bed to the chair today, for the first time. She further reported that the physicians are unsure as to the cause of the seizures, but that they have ruled out infection and the mri ruled out any brain problems. It is the opinion of the company's chief medical officer (cmo) that the time of the seizure as being 2 days post pdt as well as uneventful responses to levulan pdt suggest to me that the pdt treatment is unrelated to the seizure episode.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number1226354-2013-00082
MDR Report Key3560371
Report Source05
Date Received2013-11-12
Date of Report2013-10-22
Date of Event2013-10-18
Date Facility Aware2013-10-22
Date Mfgr Received2013-10-22
Device Manufacturer Date2010-10-01
Date Added to Maude2014-02-05
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactJOANNE LAVALLE, RAC
Manufacturer Street25 UPTON DR.
Manufacturer CityWILMINGTON MA 01887
Manufacturer CountryUS
Manufacturer Postal01887
Manufacturer Phone9786577500
Manufacturer G1DUSA PHARMACEUTICALS, INC.
Manufacturer Street25 UPTON DR.
Manufacturer CityWILMINGTON MA 01887
Manufacturer CountryUS
Manufacturer Postal Code01887
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameBLU-U BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATORE
Generic NameBLU-U
Product CodeMVF
Date Received2013-11-12
Model NumberBLU-U 10K
Catalog NumberMODEL 4170-ID
Lot NumberNA
ID NumberNA
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Age3 YR
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerDUSA PHARMACEUTICALS, INC.
Manufacturer AddressWILMINGTON MA US


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization; 2. Life Threatening 2013-11-12

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.